Bristol-Myers Squibb Co Company Profile (NYSE:BMY)

About Bristol-Myers Squibb Co (NYSE:BMY)

Bristol-Myers Squibb Co logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:BMY
  • CUSIP: 11012210
  • Web:
  • Market Cap: $88.66 billion
  • Outstanding Shares: 1,647,434,000
Average Prices:
  • 50 Day Moving Avg: $54.23
  • 200 Day Moving Avg: $55.27
  • 52 Week Range: $46.01 - $77.12
  • Trailing P/E Ratio: 18.69
  • Foreward P/E Ratio: 17.14
  • P/E Growth: 1.98
Sales & Book Value:
  • Annual Revenue: $19.97 billion
  • Price / Sales: 4.44
  • Book Value: $8.75 per share
  • Price / Book: 6.15
  • Annual Dividend: $1.56
  • Dividend Yield: 2.9%
  • EBIDTA: $6.89 billion
  • Net Margins: 22.94%
  • Return on Equity: 31.39%
  • Return on Assets: 14.48%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 1.47%
  • Quick Ratio: 1.30%
  • Average Volume: 9.14 million shs.
  • Beta: 1
  • Short Ratio: 2.81

Frequently Asked Questions for Bristol-Myers Squibb Co (NYSE:BMY)

What is Bristol-Myers Squibb Co's stock symbol?

Bristol-Myers Squibb Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb Co pay dividends? What is the dividend yield for Bristol-Myers Squibb Co?

Bristol-Myers Squibb Co announced a quarterly dividend on Thursday, March 2nd. Investors of record on Friday, April 7th will be given a dividend of $0.39 per share on Monday, May 1st. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date is Wednesday, April 5th. View Bristol-Myers Squibb Co's Dividend History.

How were Bristol-Myers Squibb Co's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) issued its quarterly earnings data on Thursday, April, 27th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.72 by $0.12. The company earned $4.93 billion during the quarter, compared to analysts' expectations of $4.75 billion. Bristol-Myers Squibb Co had a net margin of 22.94% and a return on equity of 31.39%. Bristol-Myers Squibb Co's revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the company earned $0.74 earnings per share. View Bristol-Myers Squibb Co's Earnings History.

When will Bristol-Myers Squibb Co make its next earnings announcement?

Bristol-Myers Squibb Co is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Bristol-Myers Squibb Co.

What guidance has Bristol-Myers Squibb Co issued on next quarter's earnings?

Bristol-Myers Squibb Co issued an update on its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $2.85-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.80.

Where is Bristol-Myers Squibb Co's stock going? Where will Bristol-Myers Squibb Co's stock price be in 2017?

20 analysts have issued 12-month target prices for Bristol-Myers Squibb Co's shares. Their predictions range from $42.00 to $75.00. On average, they anticipate Bristol-Myers Squibb Co's stock price to reach $62.47 in the next twelve months. View Analyst Ratings for Bristol-Myers Squibb Co.

What are analysts saying about Bristol-Myers Squibb Co stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb Co stock:

  • 1. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
  • 2. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
  • 3. According to Zacks Investment Research, "Bristol-Myers key products – Opdivo, Orencia, Eliquis and Sprycel – should continue to fuel top-line growth of the company. The company raised its 2016 earnings guidance buoyed by strong trends across the business and posted an encouraging 2017 earnings outlook. Meanwhile, Bristol-Myers’ efforts to develop its pipeline are impressive. However, shares are under pressure with investors expressing disappointment over the company’s failed efforts to expand its key product Opdivo’s label to include the first-line treatment of lung cancer, which could give an edge to its competitors. The company announced that it will not seek an accelerated approval in the U.S. for Opdivo plus Yervoy, for first-line lung cancer. Shares of the company have underperformed that of the industry in the last one year. Moreover, estimates have come down ahead of the fourth-quarter results." (1/24/2017)
  • 4. BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)

Are investors shorting Bristol-Myers Squibb Co?

Bristol-Myers Squibb Co saw a decrease in short interest in April. As of April 28th, there was short interest totalling 18,408,873 shares, a decrease of 17.6% from the April 13th total of 22,344,818 shares. Based on an average daily trading volume, of 8,609,026 shares, the short-interest ratio is presently 2.1 days. Approximately 1.1% of the shares of the stock are sold short.

Who are some of Bristol-Myers Squibb Co's key competitors?

Who owns Bristol-Myers Squibb Co stock?

Bristol-Myers Squibb Co's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.18%), BlackRock Inc. (5.89%), State Street Corp (4.18%), FMR LLC (2.62%), Jennison Associates LLC (1.31%) and Bank of New York Mellon Corp (1.10%). Company insiders that own Bristol-Myers Squibb Co stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb Co.

Who sold Bristol-Myers Squibb Co stock? Who is selling Bristol-Myers Squibb Co stock?

Bristol-Myers Squibb Co's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Jana Partners LLC, FMR LLC, Vontobel Asset Management Inc., Westfield Capital Management Co. LP, American Century Companies Inc., TIAA CREF Investment Management LLC and Neuberger Berman Group LLC. Company insiders that have sold Bristol-Myers Squibb Co stock in the last year include John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler and Sandra Leung. View Insider Buying and Selling for Bristol-Myers Squibb Co.

Who bought Bristol-Myers Squibb Co stock? Who is buying Bristol-Myers Squibb Co stock?

Bristol-Myers Squibb Co's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., Ameriprise Financial Inc., Sachem Head Capital Management LP, Thrivent Financial For Lutherans, Primecap Management Co. CA and Geode Capital Management LLC. View Insider Buying and Selling for Bristol-Myers Squibb Co.

How do I buy Bristol-Myers Squibb Co stock?

Shares of Bristol-Myers Squibb Co can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bristol-Myers Squibb Co stock cost?

One share of Bristol-Myers Squibb Co stock can currently be purchased for approximately $53.82.

Analyst Ratings

Consensus Ratings for Bristol-Myers Squibb Co (NYSE:BMY) (?)
Ratings Breakdown: 1 Sell Rating, 10 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $62.47 (16.07% upside)

Analysts' Ratings History for Bristol-Myers Squibb Co (NYSE:BMY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017BMO Capital MarketsDowngradeMarket Perform -> Underperform$47.00MediumView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
3/11/2017Jefferies Group LLCReiterated RatingBuy$64.00 -> $66.00N/AView Rating Details
3/8/2017Piper Jaffray CompaniesReiterated RatingNeutral$60.00MediumView Rating Details
2/22/2017ArgusReiterated RatingBuy$75.00N/AView Rating Details
2/16/2017Deutsche Bank AGReiterated RatingHold$42.00N/AView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/30/2017Leerink SwannReiterated RatingOutperform$62.00N/AView Rating Details
1/24/2017Barclays PLCLower Price TargetEqual Weight$65.00 -> $58.00N/AView Rating Details
1/21/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
1/20/2017Cowen and CompanyDowngradeOutperform -> Market Perform$77.12 -> $65.00N/AView Rating Details
1/20/2017William BlairReiterated RatingOurperformN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
11/8/2016Citigroup IncReiterated RatingBuyN/AView Rating Details
10/28/2016Hilliard LyonsUpgradeNeutral -> Buy$69.00N/AView Rating Details
10/17/2016Credit Suisse Group AGReiterated RatingHold$58.00N/AView Rating Details
10/13/2016Goldman Sachs Group IncDowngradeStrong-Buy -> Buy$75.00N/AView Rating Details
10/10/2016SunTrust Banks, Inc.Reiterated RatingHold$68.00 -> $62.00N/AView Rating Details
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldN/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00N/AView Rating Details
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Bristol-Myers Squibb Co (NYSE:BMY)
Earnings by Quarter for Bristol-Myers Squibb Co (NYSE:BMY)
Earnings History by Quarter for Bristol-Myers Squibb Co (NYSE:BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017$0.72$0.84$4.75 billion$4.93 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bristol-Myers Squibb Co (NYSE:BMY)
2017 EPS Consensus Estimate: $2.82
2018 EPS Consensus Estimate: $3.00
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.70$0.72$0.71
Q2 20173$0.73$0.73$0.73
Q3 20173$0.71$0.73$0.72
Q4 20173$0.62$0.68$0.66
Q1 20181$0.70$0.70$0.70
Q2 20181$0.72$0.72$0.72
Q3 20181$0.77$0.77$0.77
Q4 20181$0.81$0.81$0.81
(Data provided by Zacks Investment Research)


Current Dividend Information for Bristol-Myers Squibb Co (NYSE:BMY)
Most Recent Dividend:5/1/2017
Annual Dividend:$1.56
Dividend Yield:2.90%
Dividend Growth:2.80% (3 Year Average)
Payout Ratio:58.87% (Trailing 12 Months of Earnings)
52.88% (Based on This Year's Estimates)
49.68% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Bristol-Myers Squibb Co (NYSE:BMY)

Dividend History by Quarter for Bristol-Myers Squibb Co (NYSE:BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Bristol-Myers Squibb Co (NYSE:BMY)
Insider Ownership Percentage: 0.24%
Institutional Ownership Percentage: 69.67%
Insider Trades by Quarter for Bristol-Myers Squibb Co (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb Co (NYSE:BMY)
Insider Trades by Quarter for Bristol-Myers Squibb Co (NYSE:BMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.00View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.84View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.00View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Bristol-Myers Squibb Co (NYSE:BMY)
Latest Headlines for Bristol-Myers Squibb Co (NYSE:BMY)
DateHeadline logoBristol-Myers Squibb (BMY) Announces FDA Accepts Opdivo sBLA for Priority Review for Treatment of HCC - - May 24 at 8:55 PM logoU.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma - May 24 at 12:54 PM logoCatch Bristol-Myers Squibb Co (BMY) Stock With Confidence - - May 23 at 4:03 PM logoWhat Orencia Meant to BMY in 1Q17 - May 22 at 11:52 AM logoCatch Bristol-Myers Squibb Co (BMY) Stock With Confidence - May 22 at 10:31 AM logoBehind BMY’s Cardiovascular Performance in 1Q17 - May 19 at 3:54 PM logoStock Traders Buy Large Volume of Bristol-Myers Squibb Put Options (BMY) - May 19 at 1:46 PM logoTraders Purchase Large Volume of Call Options on Bristol-Myers Squibb (BMY) - May 19 at 1:46 PM logoEMA Validates Application For Bristol-Myers' Sprycel In Children With CML - May 19 at 9:04 AM logoThe Hot Stock: Incyte Climbs - May 19 at 9:04 AM logoWhat Happened to Bristol-Myers Squibb’s Opdivo in 1Q17? - May 19 at 9:04 AM logoEuropean Medicines Agency Validates Application for Bristol-Myers Squibb’s Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia - May 19 at 9:04 AM logoBehind Bristol-Myers Squibb’s 1Q17 Performance - May 18 at 11:39 AM logoUnderstanding Bristol-Myers Squibb’s Oncology Performance in 1Q17 - May 18 at 11:39 AM logoBristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 - May 17 at 9:01 PM logoBristol - Myers Squibb Partnering Deals and Alliances 2010 to 2017 - May 16 at 4:05 PM logoI Think Bristol-Myers Squibb Has Finally Bottomed - May 16 at 12:34 PM logoBristol-Myers Squibb to Take Part in UBS Global Healthcare Conference - May 16 at 12:34 PM logoEli Lilly: Has This Bloom Begun To Wilt? - May 16 at 12:34 PM logoQ3 2017 EPS Estimates for Bristol-Myers Squibb Co Lowered by Analyst (BMY) - May 15 at 8:18 AM logoBristol-Myers Squibb Co (BMY) Short Interest Update - May 15 at 7:24 AM logoBRIEF-Appaloosa LP dissolves share stake in Bristol Myers, Qualcomm - May 12 at 9:37 PM logoBristol-Myers Squibb Co (BMY) Earns "Overweight" Rating from JPMorgan Chase & Co. - May 11 at 9:02 PM logoMerck: Seal of Approval? - May 11 at 4:31 PM logoHere's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers - May 11 at 12:31 PM logoHere's Why Calithera Biosciences Stock Gained as Much as 16.4% Today - May 10 at 4:29 PM logoWhy Roche's Cancer Failure Might Tank Bristol, Pfizer — But Not Merck - May 10 at 4:11 PM logoHere's Why Calithera Biosciences Stock Gained as Much as 16.4% Today - May 10 at 4:11 PM logoBRIEF-Bristol-Myers Squibb, Calithera Biosciences expand collaboration - May 10 at 8:44 AM logoRoche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers - May 10 at 8:44 AM logoBristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : May 10, 2017 - May 10 at 8:44 AM logoCelldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update - May 9 at 9:01 PM logoBuy 'repatriation stocks' because that is sure to make the cut in the final tax bill, UBS says - May 9 at 3:59 PM logoVeeva Commercial Cloud to Help Bristol-Myers Squibb Deliver More Efficient and Effective Customer Engagement - May 8 at 3:51 PM logoJ&J: What's In Store At Next Week's Analyst Meeting - May 8 at 10:27 AM logoBristol-Myers Squibb Sees Unusually Large Options Volume (BMY) - May 7 at 7:14 AM logoNear-Term Events Cast Shadow Of Uncertainty On Bristol-Myers - May 6 at 4:21 PM logo$5.07 Billion in Sales Expected for Bristol-Myers Squibb Co (BMY) This Quarter - May 6 at 8:46 AM logoSomewhat Favorable Media Coverage Very Likely to Affect Bristol-Myers Squibb (BMY) Share Price - May 6 at 12:32 AM logoBMO Capital Downgrades Bristol-Myers Squibb Co. (BMY) to Underperform - - May 5 at 9:01 PM logo Analysts Expect Bristol-Myers Squibb Co (BMY) Will Post Earnings of $0.73 Per Share - May 4 at 4:12 PM logoStill Some Uncertainty Surrounding Bristol-Myers Squibb - May 3 at 9:02 PM logoBristol-Myers: Going Stag to the Ball? - May 3 at 4:01 PM logoBristol-Myers 'Too Risky' To Acquire As Merck, Roche Pile On Pressure - May 3 at 4:01 PM logoBristol-Myers Stock Falls Following Ratings Cut at BMO - May 3 at 4:01 PM logoFY2017 Earnings Forecast for Bristol-Myers Squibb Co (BMY) Issued By Jefferies Group - May 3 at 1:45 PM logoBMO Capital Downgrades Bristol-Myers Squibb Co. (BMY) to Underperform - May 3 at 9:24 AM logoAnalysts' Actions -- Anadarko, FireEye, Bristol-Myers, Twilio and More - May 3 at 9:24 AM logoBristol-Myers Squibb (BMY) Receives Daily Coverage Optimism Rating of 0.10 - May 3 at 12:00 AM logoGilead Topples On Consensus-Lagging Q1 As Hepatitis C Drug Sales Plummet - May 2 at 7:02 PM



Bristol-Myers Squibb Co (BMY) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff